MarketScreener lists TWD 240.00 target for Caliway Biopharmaceuticals C stock
Published on 10/14/2026 at 08:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and trial data
- MarketScreener listed a TWD 240.00 average target from one analyst on September 15, 2026.
- Phase 2 results showed a 69.60 percent response rate against 0.00 percent for placebo.
- Caliway Biopharmaceuticals C stock costs TWD 78.30 at 1:30 p.m. TST on October 14, 2026, up 2.35 percent versus the Taiwan Stock Exchange close of TWD 76.50 and 58.35 percent below its 52-week high.
- Investing.com lists November 11, 2026, as the next earnings date.
MarketScreener listed a TWD 240.00 average target from one analyst for Caliway Biopharmaceuticals C on September 15, 2026. Against the TWD 78.30 Taiwan Stock Exchange price on October 14, 2026, that target lies 206.51 percent above the stock. The stock was last at TWD 78.30 on the Taiwan Stock Exchange on October 14, 2026 at 1:30 p.m. TST, up 2.35 percent versus the Taiwan Stock Exchange close of TWD 76.50.
Phase 2 response reaches 69.60 percent
Pharmaphorum reported that 69.60 percent of participants receiving CBL-514 achieved at least 150 mL of subcutaneous fat reduction at the eight-week follow-up, compared with 0.00 percent for placebo. That comparison gives the clinical program a measurable distinction, while the treatment remains in development and the phase 3 program still has to establish safety and efficacy in larger groups.
On October 2, 2026, Caliway Biopharmaceuticals said recruitment had started for the first of two phase 3 trials. The company described the studies as randomized and placebo-controlled, with initial results expected at the end of 2027.
Stock sits 58.35 percent below its high
The Taiwan Stock Exchange price of TWD 78.30 stands 4.26 percent above the 52-week low of TWD 75.10 and 58.35 percent below the 52-week high of TWD 188.00. Trading volume reached 2,922,844 shares on October 14, 2026, against an average volume of 6,895,037 shares.
Results date is November 11, 2026
Investing.com lists November 11, 2026, as Caliway's next earnings date. The latest reported second-quarter 2026 figures were TWD 3.57 million of revenue and a TWD 222.52 million net loss, according to the same earnings page.
Taiwan valuation remains clinical-stage
Caliway carried a market capitalization of TWD 121.9 billion on October 14, 2026. The company operates in healthcare biotechnology and is developing CBL-514 for aesthetic medicine and chronic inflammation applications, while CBA-539 remains in preclinical exploration.
Taiwan price stays above its low
The TWD 78.30 price and the TWD 76.50 Taiwan Stock Exchange close frame the day's move for US-based readers, while the 52-week range shows that the stock remains near its annual low. The clinical data and the November reporting date provide the next measurable checkpoints for the company's development program.
Market context: Market report TAIEX.
Caliway Biopharmaceuticals C market facts
- Company: Caliway Biopharmaceuticals Co., Ltd.
- ISIN: TW0006919004
- Ticker: 6919
- Primary exchange: Taiwan Stock Exchange
- Price Taiwan Stock Exchange (as of October 14, 2026, 1:30 p.m. TST): TWD 78.30
- Change versus Taiwan Stock Exchange close: plus 2.35 percent
- Taiwan Stock Exchange close (October 14, 2026): TWD 76.50
- Market capitalization: TWD 121.9 billion (as of October 14, 2026)
- 52-week range: TWD 75.10-TWD 188.00 (as of October 14, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: November 11, 2026
Market context: Market report TAIEX.
More news and analyses on Caliway Biopharmaceuticals C stock
